论文部分内容阅读
目的探讨microRNA-155(miR-155)在甲状腺乳头状癌(papillary thyroid cancer,PTC)患者中的表达情况及与临床病理特征的相关性,miR-155指导PTC预后的可行性。方法收集86例PTC患者的癌及癌旁新鲜组织,用荧光定量PCR的方法检测miR-155在上述组织中的表达,并结合其临床病理特点进行回顾性分析。结果 69.8%(60/86)的PTC患者癌组织的miR-155表达较癌旁正常组织上调,相对上调倍数为2.63±2.73倍;而在表达上调组中,PTC原发灶更大[(1.66±0.96)cm vs(1.19±0.52)cm,P=0.021];更容易出现甲状腺包膜外侵犯(56.7%vs 23.1%,P=0.004);淋巴结转移率更高(70%vs 46.2%,P=0.036);具有更晚的TNM分期,Ⅲ~Ⅳ期的比例更高(20%vs 0%,P=0.014)。PTC癌组织中miR-155相对表达量(ΔCT)高低与淋巴结转移个数具备一定的相关性(r=0.531,P=0.001)。结论 PTC中miR-155的高表达具有更大肿瘤病灶,更易甲状腺包膜外侵犯,更高颈部淋巴结转移率及更晚的TNM分期等临床病理特点,可能作为不良临床预后的判断指标之一。
Objective To investigate the expression of microRNA-155 (miR-155) in the patients with papillary thyroid cancer (PTC) and the correlation with the clinicopathological features. The feasibility of miR-155 in guiding the prognosis of PTC was explored. Methods Tissues from 86 patients with PTC were collected for cancer and adjacent tissues. The expression of miR-155 in these tissues was detected by fluorescence quantitative polymerase chain reaction (RT-PCR), and the clinicopathological features were analyzed retrospectively. Results The expression of miR-155 in 69.8% (60/86) of the cancer tissues was up-regulated compared with the normal tissue adjacent to cancer (2.63 ± 2.73 fold), while in the up-regulated group, the primary tumor was larger (1.66 ± 0.96) cm vs (1.19 ± 0.52) cm, P = 0.021]. Thyroid extracapsular invasion was more likely to occur (56.7% vs 23.1%, P = 0.004); lymph node metastasis was higher (70% vs 46.2%, P = 0.036). With a later TNM stage, the proportion of stage III to IV was higher (20% vs 0%, P = 0.014). The relative expression of miR-155 (ΔCT) in PTC tissues correlated with lymph node metastasis (r = 0.531, P = 0.001). Conclusion The high expression of miR-155 in PTC has the clinical features of larger tumor focus, more invasive thyroid gland invasion, higher cervical lymph node metastasis and later TNM stage, which may be one of the indicators to judge the adverse clinical prognosis .